Want to see INBS full AI Analyst Report?
Intelligent Bio Solutions (INBS) AI Stock Analysis
Intelligent Bio Solutions
(NASDAQ:INBS)
The score is held down primarily by weak financial quality—large ongoing losses, declining gross margin, and significant persistent cash burn—combined with bearish technicals (price below all key moving averages and negative MACD). Offsetting these are positive corporate developments around the FDA 510(k) submission and recent financing, which modestly improve the risk/reward profile despite still-limited valuation support due to negative earnings.
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.87M
- Dividend Yield
- ―
- Average Volume (3M)
- 143.43K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 1.39
- Revenue Growth
- 38.09%
- EPS Growth
- 54.22%
- Country
- US
- Employees
- 59
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Intelligent Bio Solutions Business Overview & Revenue Model
Company Description
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Sali...
How the Company Makes Money
INBS primarily makes money by selling and distributing its rapid drug screening system and the recurring consumables used with it. Key revenue streams include: (1) sales of the screening platform/instrument to customers and channel partners; (2) ongo...
Intelligent Bio Solutions Financial Statement Overview
Summary
Revenue is improving (TTM ~$4.2M vs. ~$3.1M prior), but the business remains highly unprofitable with very weak margins (net margin roughly -297% TTM) and declining gross margin (~32% TTM vs. ~41–46% previously). Cash flow is the biggest risk with persistent, deep operating and free-cash-flow losses (OCF about -$12.1M; FCF about -$12.2M TTM), implying continued reliance on external funding despite manageable leverage (debt-to-equity about 0.21 TTM).
Income Statement
23NegativeBalance Sheet
48NeutralCash Flow
18Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.22M | 4.22M | 3.05M | 3.11M | 1.26M | 0 |
| Gross Profit | 1.17M | 2.05M | 1.25M | 1.43M | 326.67K | 0 |
| EBITDA | -8.85M | -11.29M | -9.21M | -8.81M | -9.47M | -8.33M |
| Net Income | -12.43M | -12.43M | -10.57M | -10.16M | -10.63M | -8.31M |
Balance Sheet | ||||||
| Total Assets | 11.94M | 11.94M | 8.25M | 13.78M | 10.35M | 12.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.99M | 3.99M | 1.02M | 6.30M | 1.54M | 8.28M |
| Total Debt | 1.82M | 1.82M | 281.81K | 1.15M | 1.92M | 0 |
| Total Liabilities | 6.65M | 6.65M | 5.44M | 5.60M | 6.67M | 5.81M |
| Stockholders Equity | 5.51M | 5.51M | 3.00M | 8.33M | 3.80M | 6.62M |
Cash Flow | ||||||
| Free Cash Flow | -12.20M | -12.05M | -9.91M | -9.79M | -7.88M | -3.74M |
| Operating Cash Flow | -12.08M | -11.93M | -9.68M | -9.57M | -7.38M | -3.36M |
| Investing Cash Flow | -87.49K | -85.57K | -231.84K | -221.43K | -694.14K | -880.22K |
| Financing Cash Flow | 15.25M | 14.98M | 4.60M | 14.56M | 1.44M | 0 |
Intelligent Bio Solutions Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Positive. The current price of 1.77 is above the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.85, and below the 200-day MA of 3.05, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.45 is Neutral, neither overbought nor oversold. The STOCH value of 50.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBS.
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions disclosed 58 risk factors in its most recent earnings report. Intelligent Bio Solutions reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksIntelligent Bio Solutions Peers Comparison
Overall Rating
- INBS44Neutral
BIAF43Neutral
ISPC41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INBS | 44Neutral | $5.51M | -0.19 | -170.36% | ― | 38.09% | 54.22% |
| BIAF | 43Neutral | $3.84M | -0.03 | -257.27% | ― | -23.17% | 67.18% |
| ISPC | 41Neutral | $2.10M | -0.01 | -524.37% | ― | -92.11% | 86.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| INBS | Intelligent Bio Solutions Inc. | 1.77 | -6.46 | -78.49% | |
| ISPC | Ispecimen Inc | 0.79 | -26.17 | -97.07% | |
| BGLC | Bionexus Gene Lab Corporation | 0.95 | -4.44 | -82.37% | |
| BIAF | bioAffinity Technologies, Inc. | 3.19 | -29.36 | -90.20% |
Intelligent Bio Solutions Corporate Events
Intelligent Bio Solutions Releases New Investor Presentation Update
NeutralOn October 12, 2026, Intelligent Bio Solutions Inc.’s board adopted Second Amended and Restated Bylaws, clarifying that, for matters other than director elections, outcomes at stockholder meetings are determined by a majority of votes cast, exc...
Intelligent Bio Solutions Updates Share Capital Structure
NeutralIntelligent Bio Solutions reported changes in its share capital structure following recent corporate actions. The update reflects both the exercise of prefunded warrants and the issuance of restricted shares under an advisory agreement. As a result o...
Intelligent Bio Solutions Advances FDA Drug Screening Filing
PositiveOn September 9, 2026, Intelligent Bio Solutions announced it had submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The move caps a...
Intelligent Bio Solutions Completes $5 Million Private Placement
PositiveOn August 31, 2026, Intelligent Bio Solutions entered a securities purchase agreement with a single existing institutional investor for a private placement of common stock or pre-funded warrants, plus Series N-1 and Series N-2 warrants, priced at-the...
Intelligent Bio Solutions Advances Fingerprint Drug Test Toward FDA
PositiveOn September 1, 2026, Intelligent Bio Solutions Inc. reported results from a multi-site Method Comparison Study of its Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine in pre-employment and workplace settings across t...
Intelligent Bio Solutions Issues Routine Investor Presentation Update
NeutralOn August 28, 2026, Intelligent Bio Solutions Inc. made an investor presentation available detailing its business and operations, and notified the market of this disclosure under Regulation FD. The presentation was furnished, rather than filed, under...
Intelligent Bio Solutions Advances FDA Fingerprinting Drug Study
PositiveOn August 11, 2026, Intelligent Bio Solutions announced it had completed a multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, the final clinical study supporting its FDA 510(k) program for codeine detection i...
Intelligent Bio Solutions Advances Fingerprint Drug Screening Program
PositiveOn August 5, 2026, Intelligent Bio Solutions announced it had completed a Usability Study for its Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) submission for U.S. clearance to detect the opiate codeine.Conducted...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 11, 2026